| Name | Title | Contact Details |
|---|
We are a proudly Canadian healthcare company, providing diversified healthcare services across the country.
Nu Image Medical specializes in Weight Loss, Hormone Replacement, Sexual Enhancement and General Wellness. Our futuristic methods offer a new and updated approach to achieving optimum health and wellness not only through local brick-and-mortar establishments, but also online virtually through our telemedicine platform. Nu Image Medical has been proving patient services nationally since 2004, establishing itself as not on a leader in Regenerative Medicine, but also in the Telehealth industry. Nu Image Medical sets the standard for patients looking to receive quality expert medical care without boundaries.
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.
Palo Duro Nursing Home is a Claude, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.